Incidence and Predictors of Loss to Follow-Up Among ART Patients on Follow-Up at Public Health Facilities in Southwest Ethiopia. A Time-to-Event Analysis

埃塞俄比亚西南部公共卫生机构接受抗逆转录病毒治疗(ART)患者随访期间失访的发生率及预测因素:一项生存分析

阅读:1

Abstract

BackgroundLoss to follow-up (LTFU) remains a major challenge to successful antiretroviral therapy (ART), contributing to increased morbidity, mortality, and drug resistance, particularly in Sub-Saharan Africa. Evidence on the timing and predictors of LTFU in rural Ethiopia is limited. This study aimed to determine the time to LTFU and its predictors among adults on ART in selected health facilities of Ilu Aba Bor Zone, Southwest Ethiopia.MethodsA retrospective cohort study was conducted among 372 adults living with human immune virus (HIV) on ART at 4 public health facilities from October 2018 to November 2022. Data were extracted from standardized ART forms and patient charts. Kaplan-Meier survival analysis estimated survival probabilities, and Cox proportional hazards regression identified predictors of LTFU, reporting adjusted hazard ratios with 95% confidence intervals (CI). Proportional hazards assumptions were checked using Schoenfeld residuals and log-log plots.ResultsOver 6993 person-months of follow-up (median: 19 months), 70 participants (18.8%) were LTFU, mostly within the first year (34.3% in the first 6 months; 32.9% in the second 6 months). Independent predictors included absence of a registered phone number, World Health Organization clinical stage III/IV, noninitiation of cotrimoxazole preventive therapy, nondisclosure of HIV status, and poor or fair adherence.ConclusionLTFU was common during early antiretroviral. Strengthening patient tracing, promoting disclosure, initiating preventive therapy, and improving adherence support may enhance retention and contribute to achieving human Immune deficiency virus epidemic control targets.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。